 | MERK - Merck Tbk. | MERK - Merck Tbk. | MERK - Merck Tbk. | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (5) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Index (5) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Board | : | 5 Index COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | |
|||||
| D Good | ||||||
| E Fair | ||||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 5 | |
| Rating ROA | 1 | |
| Rating EQUITY | 2 | |
| Rating ROE | 3 | |
| Rating DER | 3 | |
| Rating TOTAL | 4 | |
| MARKET CAPITALIZATION | ||
| Listed Share | 448.000.000 | |
| Price | Rp. 3.710 | |
| Capitalization | Rp. 1.662.080.000.000 | |
| OWNERSHIP | ||
| Listing Date : | ||
| Lokal 8,65 % | Asing 16,44 % | Lainnya 74,91 % |
| MERK - Merck Tbk. | MERK - Merck Tbk. | MERK - Merck Tbk. | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (5) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Index (5) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Board | : | 5 Index COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
Financial Statements
| Description | 2Q18 | 2Q19 | 2Q20 | 2Q21 | 2Q22 | 2Q23 | 2Q24 | CAGR 5Y(%) |
| Last Price | 6800 | 3980 | 2750 | 3300 | 4080 | 4700 | 3870 | |
| Market Cap | 3.0 T | 1.8 T | 1.2 T | 1.5 T | 1.8 T | 2.1 T | 1.7 T | -5.56 |
| BALANCE SHEET | ||||||||
| Cash | 138.4 B | 77.7 B | 87.2 B | 219.7 B | 129.2 B | 118.8 B | 27.9 B | -64.09 |
| Total Asset | 946.0 B | 848.8 B | 954.5 B | 940.2 B | 988.4 B | 894.5 B | 1.8 T | 112.06 |
| S.T.Borrowing | 304.5 B | 285.9 B | 285.7 B | 192.7 B | 230.1 B | 152.7 B | 565.2 B | |
| L.T.Borrowing | 52.3 B | 38.4 B | 42.7 B | 53.2 B | 58.5 B | 36.5 B | 452.9 B | |
| Total Equity | 589.3 B | 524.4 B | 626.1 B | 694.2 B | 699.9 B | 705.2 B | 744.6 B | 41.99 |
| INCOME STATEMENT | ||||||||
| Revenue | 606.0 B | 316.8 B | 282.8 B | 506.8 B | 599.6 B | 498.2 B | 1.3 T | 310.35 |
| Gross Profit | 316.9 B | 106.1 B | 124.5 B | 197.5 B | 241.8 B | 203.7 B | 179.8 B | 69.46 |
| Operating Profit | 123.9 B | 12.2 B | 43.0 B | 107.2 B | 157.4 B | 118.5 B | 160.5 B | 1215.57 |
| Net.Profit | 90.3 B | 6.1 B | 32.1 B | 81.5 B | 123.4 B | 91.4 B | 127.6 B | 1991.80 |
| EBITDA | 125.4 B | 18.2 B | 48.0 B | 112.6 B | 162.6 B | 124.3 B | 175.0 B | 861.54 |
| Interest Expense | 731.3 M | 1.7 B | 1.2 B | 562.9 M | 867.4 M | 2.3 B | 13.4 B | |
| RATIO | ||||||||
| EPS | 201.58 | 13.66 | 71.69 | 182.01 | 275.45 | 203.94 | 284.85 | 1985.29 |
| PER | 33.73 x | 291.36 x | 38.36 x | 18.13 x | 14.81 x | 23.05 x | 13.59 x | |
| BVPS | 1315.32 | 1170.54 | 1397.61 | 1549.61 | 1562.33 | 1574.21 | 1662.08 | |
| PBV | 5.17 x | 3.40 x | 1.97 x | 2.13 x | 2.61 x | 2.99 x | 2.33 x | |
| ROA | 0.0955 | 0.0072 | 0.0337 | 0.0867 | 0.1248 | 0.1021 | 0.0724 | 905.56 |
| ROE | 0.1533 | 0.0117 | 0.0513 | 0.1175 | 0.1763 | 0.1295 | 0.1714 | 1364.96 |
| EV/EBITDA | 26.04 | 111.25 | 30.69 | 13.36 | 12.22 | 17.51 | 15.56 | |
| Debt/Equity | 0.61 | 0.62 | 0.52 | 0.35 | 0.41 | 0.27 | 1.37 | |
| Debt/TotalCap | 0.38 | 0.38 | 0.34 | 0.26 | 0.29 | 0.21 | 0.58 | |
| Debt/EBITDA | 2.85 | 17.78 | 6.84 | 2.18 | 1.77 | 1.52 | 5.82 | |
| EBITDA/IntExps | 171.42 | 10.62 | 39.16 | 200.05 | 187.42 | 54.82 | 13.03 | 22.69 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | |
|||||
| D Good | ||||||
| E Fair | ||||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| MARKET CAPITALIZATION | ||
| Listed Share | 448.000.000 | |
| Price | Rp. 3.710 | |
| Capitalization | Rp. 1.662 B. | |
| OWNERSHIP | ||
| Listing Date : | ||
| Lokal 8,65 % | Asing 16,44 % | Lainnya 74,91 % |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 5 | |
| Rating ROA | 1 | |
| Rating EQUITY | 2 | |
| Rating ROE | 3 | |
| Rating DER | 3 | |
| Rating TOTAL | 4 | |
RETURN ON ASSET
| MERK - Merck Tbk. | MERK - Merck Tbk. | MERK - Merck Tbk. | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (5) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Index (5) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Board | : | 5 Index COMPOSITE, IDXSMC-COM, IDXHEALTH, ISSI, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| TIME PERIOD : 11-10-2024 | |||
| Close | 3710 | Prev Close | 3720 |
| Change | -10 (-0.3%) | Range | 3710-3720 |
| Bid | 3710 | Offer | 3730 |
| Bid Volume | 3200 | Offer Volume | 500 |
| Frequency | 27 | Value Rp.: 26.760.000 | |
| RETURN ON ASSET | |||||
|---|---|---|---|---|---|
| Benchmark to Others : | |||||
| A Exceptional | |||||
| B Excellent | |||||
| C Very Good | |
||||
| D Good | |||||
| E Fair | |||||
| F Poor | |||||
| RATIO (%) | ≤ 0 |
0-0.4 | 0.4- 1.7 |
1.7- 3.6 |
> 3.6 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | |
|||||
| D Good | ||||||
| E Fair | ||||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
